Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Neoantigen Cancer Vaccine market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Neoantigen Cancer Vaccine market. Detailed analysis of key players, along with key growth strategies adopted by Neoantigen Cancer Vaccine industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Vaccibody
Roche
Advaxis
Gritstone Oncology
Nouscom
Brightpath Biotherapeutics
Genocea
OSE Immunotherapeutics
Medimmune
Geneos Therapeutics
Neon Therapeutics
Agenus
Medigene
Merck
By Type:
Personalized Vaccine
Off-the-shelf Neovaccines
By End-User:
Hospital
Clinic
Others
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Neoantigen Cancer Vaccine Market
-
1.3 Market Segment by Type
-
1.3.1 USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Personalized Vaccine from 2016 to 2027
-
1.3.2 USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Off-the-shelf Neovaccines from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Hospital from 2016 to 2027
-
1.4.2 USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Clinic from 2016 to 2027
-
1.4.3 USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Neoantigen Cancer Vaccine Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Neoantigen Cancer Vaccine by Major Types
-
3.4.1 Market Size and Growth Rate of Personalized Vaccine
-
3.4.2 Market Size and Growth Rate of Off-the-shelf Neovaccines
4 Segmentation of Neoantigen Cancer Vaccine Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Neoantigen Cancer Vaccine by Major End-Users
-
4.4.1 Market Size and Growth Rate of Neoantigen Cancer Vaccine in Hospital
-
4.4.2 Market Size and Growth Rate of Neoantigen Cancer Vaccine in Clinic
-
4.4.3 Market Size and Growth Rate of Neoantigen Cancer Vaccine in Others
5 Market Analysis by Regions
-
5.1 USA Neoantigen Cancer Vaccine Production Analysis by Regions
-
5.2 USA Neoantigen Cancer Vaccine Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Neoantigen Cancer Vaccine Landscape Analysis
-
6.1 West USA Neoantigen Cancer Vaccine Landscape Analysis by Major Types
-
6.2 West USA Neoantigen Cancer Vaccine Landscape Analysis by Major End-Users
7 South USA Neoantigen Cancer Vaccine Landscape Analysis
-
7.1 South USA Neoantigen Cancer Vaccine Landscape Analysis by Major Types
-
7.2 South USA Neoantigen Cancer Vaccine Landscape Analysis by Major End-Users
8 Middle West USA Neoantigen Cancer Vaccine Landscape Analysis
-
8.1 Middle West USA Neoantigen Cancer Vaccine Landscape Analysis by Major Types
-
8.2 Middle West USA Neoantigen Cancer Vaccine Landscape Analysis by Major End-Users
9 Northeast USA Neoantigen Cancer Vaccine Landscape Analysis
-
9.1 Northeast USA Neoantigen Cancer Vaccine Landscape Analysis by Major Types
-
9.2 Northeast USA Neoantigen Cancer Vaccine Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Vaccibody
-
10.1.1 Vaccibody Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Roche
-
10.2.1 Roche Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 Advaxis
-
10.3.1 Advaxis Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Gritstone Oncology
-
10.4.1 Gritstone Oncology Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Nouscom
-
10.5.1 Nouscom Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
-
10.6 Brightpath Biotherapeutics
-
10.6.1 Brightpath Biotherapeutics Company Profile and Recent Development
-
10.6.2 Market Performance
-
10.6.3 Product and Service Introduction
-
10.7 Genocea
-
10.7.1 Genocea Company Profile and Recent Development
-
10.7.2 Market Performance
-
10.7.3 Product and Service Introduction
-
10.8 OSE Immunotherapeutics
-
10.8.1 OSE Immunotherapeutics Company Profile and Recent Development
-
10.8.2 Market Performance
-
10.8.3 Product and Service Introduction
-
10.9 Medimmune
-
10.9.1 Medimmune Company Profile and Recent Development
-
10.9.2 Market Performance
-
10.9.3 Product and Service Introduction
-
10.10 Geneos Therapeutics
-
10.10.1 Geneos Therapeutics Company Profile and Recent Development
-
10.10.2 Market Performance
-
10.10.3 Product and Service Introduction
-
10.11 Neon Therapeutics
-
10.11.1 Neon Therapeutics Company Profile and Recent Development
-
10.11.2 Market Performance
-
10.11.3 Product and Service Introduction
-
10.12 Agenus
-
10.12.1 Agenus Company Profile and Recent Development
-
10.12.2 Market Performance
-
10.12.3 Product and Service Introduction
-
10.13 Medigene
-
10.13.1 Medigene Company Profile and Recent Development
-
10.13.2 Market Performance
-
10.13.3 Product and Service Introduction
-
10.14 Merck
-
10.14.1 Merck Company Profile and Recent Development
-
10.14.2 Market Performance
-
10.14.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Personalized Vaccine from 2016 to 2027
-
Figure USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Off-the-shelf Neovaccines from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Hospital from 2016 to 2027
-
Figure USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Clinic from 2016 to 2027
-
Figure USA Neoantigen Cancer Vaccine Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Neoantigen Cancer Vaccine Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Neoantigen Cancer Vaccine
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Neoantigen Cancer Vaccine by Different Types from 2016 to 2027
-
Table Consumption Share of Neoantigen Cancer Vaccine by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Personalized Vaccine
-
Figure Market Size and Growth Rate of Off-the-shelf Neovaccines
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Neoantigen Cancer Vaccine by Different End-Users from 2016 to 2027
-
Table Consumption Share of Neoantigen Cancer Vaccine by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospital
-
Figure Market Size and Growth Rate of Clinic
-
Figure Market Size and Growth Rate of Others
-
Table USA Neoantigen Cancer Vaccine Production by Regions
-
Table USA Neoantigen Cancer Vaccine Production Share by Regions
-
Figure USA Neoantigen Cancer Vaccine Production Share by Regions in 2016
-
Figure USA Neoantigen Cancer Vaccine Production Share by Regions in 2021
-
Figure USA Neoantigen Cancer Vaccine Production Share by Regions in 2027
-
Table USA Neoantigen Cancer Vaccine Consumption by Regions
-
Table USA Neoantigen Cancer Vaccine Consumption Share by Regions
-
Figure USA Neoantigen Cancer Vaccine Consumption Share by Regions in 2016
-
Figure USA Neoantigen Cancer Vaccine Consumption Share by Regions in 2021
-
Figure USA Neoantigen Cancer Vaccine Consumption Share by Regions in 2027
-
Table West USA Neoantigen Cancer Vaccine Consumption by Types from 2016 to 2027
-
Table West USA Neoantigen Cancer Vaccine Consumption Share by Types from 2016 to 2027
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2016
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2021
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2027
-
Table West USA Neoantigen Cancer Vaccine Consumption by End-Users from 2016 to 2027
-
Table West USA Neoantigen Cancer Vaccine Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2016
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2021
-
Figure West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2027
-
Table South USA Neoantigen Cancer Vaccine Consumption by Types from 2016 to 2027
-
Table South USA Neoantigen Cancer Vaccine Consumption Share by Types from 2016 to 2027
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by Types in 2016
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by Types in 2021
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by Types in 2027
-
Table South USA Neoantigen Cancer Vaccine Consumption by End-Users from 2016 to 2027
-
Table South USA Neoantigen Cancer Vaccine Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2016
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2021
-
Figure South USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2027
-
Table Middle West USA Neoantigen Cancer Vaccine Consumption by Types from 2016 to 2027
-
Table Middle West USA Neoantigen Cancer Vaccine Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2016
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2021
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by Types in 2027
-
Table Middle West USA Neoantigen Cancer Vaccine Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Neoantigen Cancer Vaccine Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2016
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2021
-
Figure Middle West USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2027
-
Table Northeast USA Neoantigen Cancer Vaccine Consumption by Types from 2016 to 2027
-
Table Northeast USA Neoantigen Cancer Vaccine Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by Types in 2016
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by Types in 2021
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by Types in 2027
-
Table Northeast USA Neoantigen Cancer Vaccine Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Neoantigen Cancer Vaccine Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2016
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2021
-
Figure Northeast USA Neoantigen Cancer Vaccine Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Vaccibody
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Vaccibody
-
Figure Sales and Growth Rate Analysis of Vaccibody
-
Figure Revenue and Market Share Analysis of Vaccibody
-
Table Product and Service Introduction of Vaccibody
-
Table Company Profile and Development Status of Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche
-
Figure Sales and Growth Rate Analysis of Roche
-
Figure Revenue and Market Share Analysis of Roche
-
Table Product and Service Introduction of Roche
-
Table Company Profile and Development Status of Advaxis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Advaxis
-
Figure Sales and Growth Rate Analysis of Advaxis
-
Figure Revenue and Market Share Analysis of Advaxis
-
Table Product and Service Introduction of Advaxis
-
Table Company Profile and Development Status of Gritstone Oncology
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gritstone Oncology
-
Figure Sales and Growth Rate Analysis of Gritstone Oncology
-
Figure Revenue and Market Share Analysis of Gritstone Oncology
-
Table Product and Service Introduction of Gritstone Oncology
-
Table Company Profile and Development Status of Nouscom
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nouscom
-
Figure Sales and Growth Rate Analysis of Nouscom
-
Figure Revenue and Market Share Analysis of Nouscom
-
Table Product and Service Introduction of Nouscom
-
Table Company Profile and Development Status of Brightpath Biotherapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Brightpath Biotherapeutics
-
Figure Sales and Growth Rate Analysis of Brightpath Biotherapeutics
-
Figure Revenue and Market Share Analysis of Brightpath Biotherapeutics
-
Table Product and Service Introduction of Brightpath Biotherapeutics
-
Table Company Profile and Development Status of Genocea
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genocea
-
Figure Sales and Growth Rate Analysis of Genocea
-
Figure Revenue and Market Share Analysis of Genocea
-
Table Product and Service Introduction of Genocea
-
Table Company Profile and Development Status of OSE Immunotherapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of OSE Immunotherapeutics
-
Figure Sales and Growth Rate Analysis of OSE Immunotherapeutics
-
Figure Revenue and Market Share Analysis of OSE Immunotherapeutics
-
Table Product and Service Introduction of OSE Immunotherapeutics
-
Table Company Profile and Development Status of Medimmune
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Medimmune
-
Figure Sales and Growth Rate Analysis of Medimmune
-
Figure Revenue and Market Share Analysis of Medimmune
-
Table Product and Service Introduction of Medimmune
-
Table Company Profile and Development Status of Geneos Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Geneos Therapeutics
-
Figure Sales and Growth Rate Analysis of Geneos Therapeutics
-
Figure Revenue and Market Share Analysis of Geneos Therapeutics
-
Table Product and Service Introduction of Geneos Therapeutics
-
Table Company Profile and Development Status of Neon Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Neon Therapeutics
-
Figure Sales and Growth Rate Analysis of Neon Therapeutics
-
Figure Revenue and Market Share Analysis of Neon Therapeutics
-
Table Product and Service Introduction of Neon Therapeutics
-
Table Company Profile and Development Status of Agenus
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Agenus
-
Figure Sales and Growth Rate Analysis of Agenus
-
Figure Revenue and Market Share Analysis of Agenus
-
Table Product and Service Introduction of Agenus
-
Table Company Profile and Development Status of Medigene
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Medigene
-
Figure Sales and Growth Rate Analysis of Medigene
-
Figure Revenue and Market Share Analysis of Medigene
-
Table Product and Service Introduction of Medigene
-
Table Company Profile and Development Status of Merck
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck
-
Figure Sales and Growth Rate Analysis of Merck
-
Figure Revenue and Market Share Analysis of Merck
-
Table Product and Service Introduction of Merck
-
